The proposed bill amends existing legislation to facilitate access to individualized investigative treatments for patients suffering from life-threatening or severely debilitating diseases. Key definitions are established, including "eligible facility," "eligible patient," "general investigative treatment," and "individualized investigative treatment." The bill outlines the criteria for patients to qualify for these treatments, which include having a recommendation from their treating physician, providing informed consent, and having explored all other FDA-approved treatment options. The informed consent process is detailed, requiring documentation that explains the treatment options, potential outcomes, and financial responsibilities associated with the treatment.

Additionally, the bill includes provisions that protect physicians from licensure repercussions for recommending these treatments and ensures that no state official can obstruct a patient's access to them. It also clarifies that manufacturers and facilities are not obligated to provide these treatments and that they cannot seek reimbursement from a patient's estate if the patient dies while receiving treatment. The bill repeals certain sections of the current law that may be outdated or redundant, streamlining the process for patients seeking innovative treatment options.

Statutes affected:
Introduced, 01/29/2025: 34-51-1, 34-51-3, 34-51-4, 34-51-6, 34-51-7, 34-51-9, 34-51-10, 34-51-2, 34-51-5
Enrolled, 03/10/2025: 34-51-1, 34-51-3, 34-51-4, 34-51-6, 34-51-7, 34-51-9, 34-51-10, 34-51-2, 34-51-5